Vanguard Global Advisers
DERM icon

Vanguard Global Advisers’s Journey Medical DERM Stock Holding History

Vanguard Global Advisers’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9K Hold
4,642
– – ﹤0.01% 3202
2026
Q1 		$21.8K Buy
+4,642
New +$36K ﹤0.01% 3284

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

Vanguard Global Advisers's DERM Position: Q2 2026 in Review

Vanguard Global Advisers held its Journey Medical (DERM) position steady in Q2 2026 at 4,642 shares worth $32.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3202.

Vanguard Global Advisers first reported a position in DERM in Q1 2026 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

  • Vanguard Global Advisers held 4,642 shares of Journey Medical worth $32.9K as of Q2 2026.
  • Vanguard Global Advisers left its Journey Medical share count unchanged in Q2 2026.
  • Journey Medical made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3202 holding.
  • Vanguard Global Advisers first reported a position in Journey Medical in Q1 2026 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.